

BD gets clearance for MRSA diagnostics AI software

June 2023—BD received FDA 510(k) clearance for the BD Kiestra methicillin-resistant *Staphylococcus aureus* imaging application, which uses artificial intelligence to automate the task of inspecting Petri dishes to determine if there is bacterial growth. The application can evaluate single specimens or group together a large volume of plates with nonsignificant growth for batch review and release negative results. It uses AI algorithms to look for specific culture characteristics on the BBL Chromagar MRSA II plate. Based on that information and analysis by BD Synapsys informatics, plate images are automatically organized and sorted into meaningful worklists, the company says.

The AI-based imaging application can be used with standalone BD Kiestra ReadA systems as well as track-based BD Kiestra laboratory automation solutions.

[BD](#), 201-847-6800